- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: voclosporin.
Displaying page 1 of 1.
EudraCT Number: 2020-001467-82 | Sponsor Protocol Number: P020.051 | Start Date*: 2020-10-23 | ||||||||||||||||
Sponsor Name:Leiden University Medical Center | ||||||||||||||||||
Full Title: An Open-Label Study Evaluating Anti-Viral Effects of Voclosporin in SARS-CoV-2 Positive Kidney Transplant Recipients – the VOCOVID Study (COVID-19) | ||||||||||||||||||
Medical condition: SARS-CoV-2 infection in Kidney Transplant Recipients | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005807-37 | Sponsor Protocol Number: AUR-VCS-2020-03 | Start Date*: 2022-04-08 | |||||||||||
Sponsor Name:Aurinia Pharmaceuticals Inc. | |||||||||||||
Full Title: A Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Efficacy, Safety and Pharmacokinetics of Voclosporin in Adolescents with Lupus Nephritis | |||||||||||||
Medical condition: Lupus Nephritis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022128-63 | Sponsor Protocol Number: LX211-11 | Start Date*: 2011-03-16 |
Sponsor Name:Lux Biosciences, Inc. | ||
Full Title: A Multi-center, Double-Masked, Parallel Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Voclosporin as Therapy in Subjects with Active Non-Infectious Uveitis Involving the Inte... | ||
Medical condition: Non-Infectious Intermediate, Posterior or Pan-uveitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) IT (Completed) GB (Completed) NL (Ongoing) CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004045-81 | Sponsor Protocol Number: AUR-VCS-2016-01 | Start Date*: 2017-05-16 | |||||||||||
Sponsor Name:Aurinia Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Achieving Renal Response in Subjects with Active Lupus Ne... | |||||||||||||
Medical condition: Lupus Nephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) ES (Completed) NL (Completed) PL (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003364-51 | Sponsor Protocol Number: AUR-VCS-2012-01 | Start Date*: 2014-10-24 | |||||||||||
Sponsor Name:Aurinia Pharmaceuticals Inc. | |||||||||||||
Full Title: A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) with Placebo in Achieving Remission in Patients with Active Lupus Nephritis | |||||||||||||
Medical condition: Active lupus nephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004046-28 | Sponsor Protocol Number: AUR-VCS-2016-02 | Start Date*: 2018-05-23 | |||||||||||
Sponsor Name:Aurinia Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Controlled, Double-blind, Continuation Study Comparing the Long-term Safety and Efficacy of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Subjects with Lupus Nephritis | |||||||||||||
Medical condition: Lupus Nephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) BG (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005528-12 | Sponsor Protocol Number: VIB7734.P2.S1 | Start Date*: 2021-08-17 | |||||||||||
Sponsor Name:Viela Bio, Inc. | |||||||||||||
Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus | |||||||||||||
Medical condition: Systemic Lupus Erythematosus (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.